drugset / Trial / NCT00548301

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

NCT00548301

Phase 3 Completed Sirion Therapeutics, Inc.
RandomizedParallel-groupDouble-blind

Summary

The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide

Indications